EXODUS
Exodus Bio is a privately held US life-sciences tools company that develops automated exosome isolation systems (H-600, M-600, T-2800) using proprietary ultrasonic nano-filtration technology, serving pharmaceutical, biotech, academic, and clinical customers across 15+ countries.
- Company typePrivate
- Founded2016
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EXODUS does
Exodus Bio is a privately held US life-sciences tools company that develops and markets automated exosome isolation and purification systems under the EXODUS brand. The company's proprietary platform combines negative pressure oscillation (NPO) with double-coupled ultrasonic harmonic oscillation (HO) on dual nanoporous membranes to rapidly separate extracellular vesicles from complex biofluids, a method it positions as the world's first fully automated exosome separation device. Validated performance benchmarks include >99% protein removal, ~99% purity, ~90% yield, isolation speeds up to 200 mL/h on the H-600, and 50x yield versus ultracentrifugation from plasma samples.
The product portfolio spans three systems — EXODUS H-600 for laboratory R&D and small-scale production (10 µL–250 mL), EXODUS M-600 for medium-scale work, and EXODUS T-2800 for large-scale GMP manufacturing (0.5–10 L) with 21 CFR Part 11 software compliance — plus a fee-for-service EV Isolation offering. The company monetizes through capital equipment sales, recurring consumables (dual nanoporous membranes), and service revenue, with custom quote-based pricing and multi-year contracts. Go-to-market combines direct enterprise sales to pharmaceutical and biotech accounts with an authorized distribution network spanning 15+ countries across APAC, EMEA, and the Middle East, supplemented by content marketing, social channels, and the annual EXODUS Symposium (2025 Cambridge MA; 2026 Berkeley CA) chaired by Nobel laureate Randy Schekman.
EXODUS targets three primary customer segments: pharmaceutical and biotechnology companies requiring GMP-compliant large-scale exosome production for therapeutics and drug delivery; academic and private research laboratories conducting extracellular vesicle and biomarker discovery; and clinical research and healthcare providers using patient-derived samples for diagnostics. The company's headquarters are in San Jose, California, with a research and application center at The Engine in Cambridge, Massachusetts. Ownership is privately held with no disclosed VC or PE backing, and no funding rounds, headcount, or revenue figures are publicly disclosed.
EXODUS firmographics
Firmographics- Name
- EXODUS
- Legal name
- Exodus Bio
- Website
- https://exodusbio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Exodus Bio is a privately held US life-sciences tools company that develops automated exosome isolation systems (H-600, M-600, T-2800) using proprietary ultrasonic nano-filtration technology, serving pharmaceutical, biotech, academic, and clinical customers across 15+ countries.
- Ownership category
- akta.pro rank
EXODUS industry classification
Industry- Product category
- Life Science Laboratory Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
- akta.pro secondary industries
- Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI), Separation & Filtration Equipment (Filters, Centrifuges, Membranes) (IMAHAEAB)
Keywords
Where EXODUS is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
EXODUS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure
Revenue model
- Equipment Sales: Sale of EXODUS exosome isolation systems including H-600 (laboratory R&D) and T-2800 (large-scale GMP manufacturing) along with associated consumables and accessories.
- EV Isolation Services: Comprehensive exosome isolation and purification services for various sample types including bodily fluids, tissue lysates, plant tissues, cell culture supernatants, and microbial culture supernatants, utilizing EXODUS purification equipment.
- Consumables: Recurring revenue from consumables required for EXODUS system operation including dual nanoporous membranes and other separation consumables tailored to sample volume needs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom quote-based pricing |
Go-to-market motion4 records
Distribution channels2 records
Marketing channels7 records
EXODUS product offering
Product offeringCore offering
EXODUS Bio designs, manufactures, and sells automated exosome isolation and purification systems (EXODUS H-600, T-2800, M-600) based on proprietary ultrasonic nano-filtration technology for laboratory R&D through large-scale GMP manufacturing. The company also provides EV isolation and purification services using its own equipment for diverse biofluid, tissue, cell, microbial, and plant samples, supported by consumables such as dual nanoporous membranes.
Product overview
EXODUS Bio offers a portfolio of automated exosome isolation systems based on proprietary ultrasonic nano-filtration technology that combines negative pressure oscillation (NPO) and double-coupled ultrasonic harmonic oscillation (HO). The product line consists of three systems: EXODUS H-600 for laboratory R&D and small-scale production, EXODUS T-2800 for large-scale GMP manufacturing, and EXODUS M-600 for various sample types. The systems share core ultrasonic nano-filtration technology while differing in scale and application focus. Additionally, the company provides EV isolation services using its purification equipment.
Differentiator
Problem solved
Functional benefit
Brands
- EXODUS H-600: Laboratory R&D / Small-Scale Production automatic, label-free exosome isolation system.
- EXODUS T-2800
- EXODUS M-600
Products and services
- EXODUS H-600 An automatic, label-free, and highly efficient exosome isolation instrument for laboratory R&D and small-scale production that enables rapid isolation of high-quality, intact exosomes with up to 200 mL/h speed, ~99% purity, and ~90% yield from various biofluids and sample volumes ranging from 10 μL to 250 mL. Targeted at academic and private research laboratories conducting extracellular vesicle research, biomarker discovery, and fundamental biomedical studies.
- EXODUS T-2800 A high-efficiency exosome isolation system designed for large-scale GMP manufacturing that integrates sample pre-processing, exosome isolation, and automatic recovery in a single three-in-one workflow. Delivers >99% protein removal efficiency, particle-to-protein ratio >1×10^8 particles/μg protein, exosome concentration >1×10^11 particles/mL, and bacteria-free, low-endotoxin output across processing volumes of 0.5–10 L. Targeted at pharmaceutical and biotechnology manufacturers requiring GMP-compliant, batch-to-batch consistent production of exosome-based therapeutics, drug delivery systems, and regenerative medicine products.
- EXODUS M-600 An exosome isolation device for medium-scale production supporting various sample types, positioned between the H-600 laboratory system and the T-2800 GMP manufacturing system. Detailed specifications are available through downloadable brochure documentation on the company Resources page.
- EV Isolation Services Comprehensive exosome isolation and purification services executed on EXODUS purification equipment for diverse sample types including bodily fluids, tissue lysates, plant tissues, cell culture supernatants, and microbial culture supernatants. Services are customizable and accommodate handling of trace samples under sterilized conditions, providing researchers and manufacturers an outsourced alternative to purchasing an instrument.
Quantifiable outcome
- Protein removal efficiency >99%, purity ~99%, yield ~90%
- +5 more outcomes
Companies that use EXODUS
Customer profileSegments3 records
Ideal customer profiles3 records
EXODUS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
EXODUS partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered flagship and core.
- Randy Schekman, PhD (Symposium Chair)flagshipNobel laureate and UC Berkeley professor serving as Symposium Organization Committee Chair for EXODUS EV Symposium 2026, highlighting scientific credibility and thought leadership.
- Aijun Wang, PhD (Symposium Chair)flagshipChancellor's Fellow Professor of Surgery & Biomedical Engineering at UC Davis serving as Symposium Organization Committee Chair for EXODUS EV Symposium 2026.
- ATA Scientific InstrumentscoreAuthorized distributor for Australia providing sales and support of EXODUS products. Located in Taren Point, NSW with contact Theanos Stafidas.
- Japan Life Science Service Inc.coreAuthorized distributor for Japan providing local sales and support of EXODUS products. Located in Nihonbashi, Tokyo.
- Xcell Therapeutics InccoreAuthorized distributor for South Korea providing sales and support. Located in Gangnam District, Seoul.
- Biotek Abadi Sdn BhdcoreAuthorized distributor for Malaysia providing sales and support. Located in Shah Alam, Selangor.
- Cold Spring Biotech Corp.coreAuthorized distributor for Taiwan providing sales and support. Located in Taipei Science Park, Nangang District.
- Gibthai Co., Ltd.coreAuthorized distributor for Thailand providing sales and support. Located in Bangkok.
- Biogroup Vietnam Co. Ltd.coreAuthorized distributor for Vietnam with offices in Ho Chi Minh City and Hanoi.
- Analytik LtdcoreAuthorized distributor for UK and Ireland providing sales and support. Located in Cambridge, UK.
- ProteigenecoreAuthorized distributor for France providing sales and support. Located in Saint-Marcel.
- Distrilab B.V.coreAuthorized distributor for Netherlands providing sales and support. Located in Apeldoorn.
- B3.BIOcoreAuthorized distributor for Poland providing sales and support. Located in Warsaw.
- PT. GAIASCIENCE INDONESIAcoreAuthorized distributor for Indonesia providing sales and support. Located in Jakarta.
- BioSeencoreAuthorized distributor for UAE providing sales and support. Located in Dubai.
- Thorvacs Biotechnology LTDcoreAuthorized distributor for Turkey providing sales and support. Located in Ankara Technology Development Zone.
- Medsantek Ltd. Co.coreAuthorized distributor for Turkey providing sales and support. Located in Istanbul.
- Inabata & Co., LtdcoreAuthorized distributor for Japan providing sales and support for EXODUS products. Located in Tokyo.
- Leading Researchers, Clinicians, and Companies WorldwideflagshipInnovation partners collaborating on breakthroughs in extracellular vesicles, nanoparticles, and nanomedicine. Working together to drive scientific discovery and real-world applications using EXODUS technology.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
EXODUS competitors and assessment
Company assessmentDirect peers
- QIAGEN: QIAGEN markets exoEasy and other membrane-based exosome isolation kits used in biomarker research and diagnostics. They compete with Exodus Bio in offering standardized EV isolation solutions for research and clinical sample preparation workflows.
- Miltenyi Biotec: Miltenyi Biotec offers magnetic bead-based cell and EV isolation instruments and reagents. Their automated separation platforms serve overlapping bioprocessing and research customers, making them a direct peer in EV isolation and downstream processing workflows.
- Beckman Coulter (Danaher): Beckman Coulter manufactures Optima-series ultracentrifuges that are the dominant traditional method for exosome isolation. They represent the established incumbent technology that EXODUS's automated approach is attempting to displace in research and bioprocessing labs.
- System Biosciences (SBI): System Biosciences develops ExoQuick and other precipitation-based exosome isolation kits used widely in EV research. They compete directly with Exodus Bio by offering standardized, lower-cost exosome purification solutions to the same academic and translational customer base.
- Izon Science: Izon Science manufactures qEV size-exclusion chromatography columns for extracellular vesicle isolation. They compete directly with Exodus Bio in the EV isolation tools market by offering an alternative technology platform serving the same research and translational customers.
Broad incumbents
- Lonza: Lonza offers contract biopharmaceutical manufacturing services including cell and gene therapy with growing exosome production capabilities. They represent a large-scale incumbent that could compete with or partner on commercial-scale exosome manufacturing for biopharma customers.
- Thermo Fisher Scientific: Thermo Fisher Scientific offers laboratory instruments, bioprocessing equipment, and EV research reagents through its broad life sciences portfolio. Their scale and instrument breadth make them an incumbent that could expand into automated exosome isolation if the market grows materially.
- Bio-Techne: Bio-Techne provides a broad portfolio of exosome research reagents including the ExoDx prostate cancer diagnostic test. As a diversified public life sciences tools company, they overlap with Exodus Bio in the EV research and diagnostics market but operate at much larger scale across multiple product categories.
- Cytiva: Cytiva (formerly GE Healthcare Life Sciences) provides bioprocessing equipment and single-use consumables for biopharmaceutical manufacturing. As a major bioprocess infrastructure provider, they overlap with Exodus Bio's T-2800 GMP manufacturing positioning in the broader bioprocess tools market.
Emerging players
- RoosterBio: RoosterBio specializes in scalable manufacturing of mesenchymal stem cells and exosomes using bioreactor systems. As an emerging exosome manufacturing services provider, they share overlap with Exodus Bio's bioprocess focus but operate at an earlier commercialization stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
EXODUS social profiles
Digital presenceEXODUS compliance and trust
Trust signalCompliance2 records
EXODUS financial estimates
Financial estimateRevenue estimate
Valuation estimate
EXODUS leadership team
Management profileNumber of profiles
EXODUS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EXODUS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EXODUS
What does EXODUS do?
EXODUS Bio designs, manufactures, and sells automated exosome isolation and purification systems (EXODUS H-600, T-2800, M-600) based on proprietary ultrasonic nano-filtration technology for laboratory R&D through large-scale GMP manufacturing. The company also provides EV isolation and purification services using its own equipment for diverse biofluid, tissue, cell, microbial, and plant samples, supported by consumables such as dual nanoporous membranes.
Is EXODUS a public or private company?
EXODUS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was EXODUS founded?
EXODUS was founded in 2016. It employs 11 to 50 people.
Where is EXODUS based?
EXODUS is headquartered in Cambridge, United States, in the North America region.
How does EXODUS make money?
Three revenue lines are on record. Equipment Sales are the primary driver. The others are EV Isolation Services and consumables.
Who are EXODUS's main competitors?
Direct peers on record are QIAGEN, Miltenyi Biotec, Beckman Coulter (Danaher), System Biosciences (SBI) and Izon Science. Broad incumbents are Lonza, Thermo Fisher Scientific, Bio-Techne and Cytiva. RoosterBio is listed as an emerging player.
Does EXODUS have an API?
No public API is recorded for EXODUS.
What industry is EXODUS in?
EXODUS's product category is Life Science Laboratory Instruments. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers). Its NAICS code is 334516 and its SIC code is 8731.